Navigation Links
Portola Pharmaceuticals Announces Positive Phase II EXPERT Results,and Additional Oral and Poster Presentations at the XXI Congress of,the International Society on Thrombosis and Haemostasis (ISTH)

nticoagulant initially being studied for the prevention of venous thromboembolism in patients who have undergone orthopedic surgery. Portola expects to develop PRT054021 for additional indications including stroke prevention in patients with atrial fibrillation and secondary prevention of myocardial infarction and stroke. Factor Xa is a validated target (one for which there are approved drugs on the market), and inhibiting its activity is believed to have superior anticoagulant properties compared to other targets such as thrombin. Portola believes its oral Factor Xa inhibitor will offer several advantages, including a long half-life to support once daily dosing and a low peak-to-trough concentration ratio, resulting in consistent activity that does not require monitoring or dose adjustment. In addition, PRT054021 is not excreted in the kidneys and therefore will not require dose adjustment in patients with impaired renal function.

About PRT060128 -- Portola's ADP Receptor Antagonist

PRT060128 is an antiplatelet drug that is the only intravenous (IV) and oral ADP receptor antagonist in clinical development. Portola believes that this compound may provide significant clinical benefit through immediate, high-level platelet inhibition in the acute setting and a seamless transition to predictable, reversible platelet inhibition in the chronic setting. Portola has studied this compound in a robust Phase I clinical development program including single ascending dose and multiple ascending dose studies with the oral formulation and a single ascending dose study with the IV formulation. Based on positive results from these studies, Portola intends to initiate its Phase II program in the second half of 2007.

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc. is a privately-held biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics for acute and chronic cardiovascular and vascul
'"/>




Page: 1 2 3

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
3. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:7/2/2015)... FRANCISCO , July 2, 2015  The Green ... ), the world,s first HIPAA compliant mobile app that ... of farm-to-table fresh medical marijuana, announced today that their ... Unlike Eaze, Meadow and more than half a ... the last year, Loud Cannabis is unique in that ...
(Date:7/2/2015)... , July 2, 2015 Pharma ... stake in ZAO "Biocom" in Russia ... into the Russian pharmaceutical market which recorded RUB 765 billion ... pharmaceutical markets in the world in 2014 (IMS Health). For ... and expected to continue with this trend, projecting ...
(Date:7/2/2015)... CAMBRIDGE, Mass. , and DURHAM, N.C. ... Sciences , Inc. today announced its acquisition of assets ... Inc. (NYSE: PFE ) that had previously been ... Inc.  XRPro Sciences also acquired all of Pfizer,s rights ... re-launching the Icagen brand and will provide comprehensive services ...
Breaking Medicine Technology:New Cannabis Delivery App Gets Product to Patient in Under 7 Minutes 2Lupin Acquires Biocom in Russia 2Lupin Acquires Biocom in Russia 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4
... July 22 Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced ... July 29, 2010 , before the U.S. financial markets open. , ... Anadys will hold a conference call and webcast on ... to discuss its second quarter 2010 financial results and to provide an ...
... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that the Company will ... Wednesday, July 28, 2010 .  Neurocrine will then host a  live conference ... Thursday morning, July 29, 2010 at 8:30 a.m. Eastern Time ... , , ...
Cached Medicine Technology:Anadys Pharmaceuticals to Report Second Quarter 2010 Financial Results 2Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2010 Financial Results 2
(Date:7/4/2015)... (PRWEB) , ... July 04, 2015 , ... When a hacker gains access to someone’s ... and at the office. On Wednesday, July 1st, the FTC issued a scam alert ... part of a verification process for a password reset instigated by the hacker. All ...
(Date:7/3/2015)... ... July 03, 2015 , ... Rheumatology ... 2015 Annual Conference , the premiere continuing education and networking event for ... SeaWorld in Orlando, Florida. Speakers include the leading rheumatology experts in immunology, ...
(Date:7/3/2015)... ... July 03, 2015 , ... The ... June 25, 2015 at 1:00pm. The Association welcomed speaker C. Daniel McGillicuddy Esq. ... bicyclists and practical points of investigating these types of cases. , Each year, ...
(Date:7/3/2015)... ... 03, 2015 , ... " Selfie on a Stick ” was featured on ... technology products available to consumers. Amanda Forstrom, a technology expert and special reporter for ... for documenting memories. , Almost every smartphone has an incredibly powerful camera built into ...
(Date:7/2/2015)... ... ... LLC. is pleased to announce the opening of its newest location in Dallas, Texas. The ... frozen yogurt chain was listed as #22 on the Inc. 500 list of fastest growing ... Lake, is located at:, 3701 W. Northwest Highway, STE 430, Dallas, TX 75220 , “We ...
Breaking Medicine News(10 mins):Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 2Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 3Health News:New FTC Scam Alert Shows Latest Example of Social Engineering Dangers 4Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Attorney from William Mattar Leads Discussion on Bicycle Accidents 2Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:sweetFrog Opens 18th Location in the Lone Star State 2
... Using the Electronic Health Record to actively engage ... blood sugar and cholesterol levels, better vaccination compliance and ... study. , Geisinger Health System launched an Electronic ... in 2005. A study published in Aprils Journal of ...
... and Cons of Approach to Eliminating HAIs, ORLANDO, ... emerging drive to eliminate infections acquired in hospitals -,is ... that the approach is overly simplistic and potentially dangerous ... Healthcare experts will,discuss the hot-button issue at the Annual ...
... critical lack of,family and paraprofessional caregivers for older ... the Community College Caregiver Training,Initiative for a second ... Caregiving Project for Older,Americans, a project housed within ... for Proposals (RFP) and will award up to,twelve ...
... (Nasdaq: NXXI ), a developer and marketer of ... cardiovascular,health, enhance memory and address chronic joint pain today ... Company,s Board of Directors,effective April 7, 2008., Mr. ... Iceland,Health, Inc. a company acquired by Nutrition 21 in ...
... blood or bone marrow is caused by mutations ... healthy blood. To devise effective therapies it is crucial ... type gives rise to leukaemic cells. Researchers from the ... Bioinformatics Institute, UK, and the Universities of Harvard, USA, ...
... Celebrates 40 Years of Specialized ... the U.S. and Abroad April 13-19, MT LAUREL, N.J., April ... the United States, the world and Enterostomal,Therapy (ET) Nursing. The end ... beginning of the end of the,Vietnam War influenced world events. And ...
Cached Medicine News:Health News:Geisinger improves care for thousands of diabetics through use of the Electronic Health Record 2Health News:The 'Zero' Mentality: Is It Good for Infection Control? 2Health News:ILC-USA and MetLife Foundation Launch Second Year of Community College Caregiver Training Grants 2Health News:Nutrition 21 Elects Mark H. Stenberg to Board of Directors 2Health News:An unexpected way to cause leukemia 2Health News:WOCN: Around the World in 40 Years 2Health News:WOCN: Around the World in 40 Years 3Health News:WOCN: Around the World in 40 Years 4
... Maximum, Maximum Xtra, and Maximum ACT ... standard and specialty hemostasis introducers in ... the premier hemostasis introducers for use ... including angiography, angioplasty, stenting, atherectomy, temporary ...
... hemostasis introducers provide outstanding insertion ... dilator-to-sheath transitions, high kink resistance ... dual layer sheath cannula provides ... works with an extra strong ...
Bx VELOCITY Coronary Stent with HEPACOAT...
A steerable diagnostic catheter with optimal maneuverability...
Medicine Products: